Genetic Profiling for Personalized CBD Epilepsy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for epilepsy, particularly treatment-resistant epilepsy, have variable responses to cannabidiol (CBD) due to unknown mechanisms, and there is a lack of studies evaluating genetic variations' influence on CBD's efficacy and tolerability.
Innovation Solution
A method involving genomics assays to identify genetic variants in specific genes associated with CBD metabolism and transport, allowing for personalized treatment decisions, including dosage adjustments and monitoring for adverse events.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CBD treatment is administered to patients with treatment-resistant epilepsy, then seizure control may be improved, but response variability is high and mechanisms are not fully understood
Solution Approach 1:
The patent performs genotyping assays before initiating CBD treatment to identify patients with specific genetic profiles (CYP2C19, CYP3A4, ABCB1 variants) who are more likely to respond to CBD therapy. This preliminary genetic screening enables personalized treatment selection, reducing response variability by pre-identifying suitable candidates before treatment begins.
2Reliability
If genetic testing is performed to identify patients who will benefit from CBD treatment, then treatment efficacy is improved, but diagnostic time and complexity increase
Solution Approach 1:
The patent segments the diagnostic process into distinct genetic markers (CYP2C19, CYP3A4, ABCB1) that can be tested independently. This segmentation allows clinicians to focus on specific genetic variants associated with CBD metabolism and transport, simplifying the overall diagnostic approach while maintaining high treatment efficacy through targeted genetic screening.
3Reliability
If CBD dosage is increased to improve seizure control, then therapeutic effect may be enhanced, but adverse events increase
Solution Approach 1:
The patent uses genetic profiling to identify patients with variants in CYP2C19, CYP3A4, and ABCB1 genes that affect CBD metabolism and transport. Based on these genetic parameters, personalized dosage regimens are prescribed, optimizing the balance between therapeutic effect and adverse events by tailoring dosage to individual metabolic capabilities rather than using fixed dosing protocols.
Data Source
AI summary
The present invention relates to the identification of a group of patients with epilepsy who will benefit from treatment with the compound cannabidiol (CBD), and to treatment of that group with CBD. The patients are identified by having variance in specific genes. Also provided is a method for identification of a group of patients with epilepsy at an increased risk of experiencing an adverse event when taking CBD.